Chabner BA, Myers CE: Clinical pharmacology of cancer chemotherapy, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer Principles & Practice of Oncology (ed 3). Philadelphia, PA, Lippincott, 1989 , pp 349-395
2.
Groopman JE, Molina JM, Scadden DT: Hematopoietic growth factors. Biology and clinical applications. N Engl J Med321:1449-1459,1989
3.
Gelman RS, Tormey DC, Betensky R., et al: Actual versus ideal weight in the calculation of surface area: Effects on dose of 11 chemotherapy agents. Cancer Treat Rep71:907-911, 1987
4.
Volkin RL, Shadduck RK, Winkelstein A., et al: Potentiation of carmustine-cranial irradiation-induced myelosuppression by cimetidine. Arch Intern Med142:243-244, 1982
5.
Gralla RJ, Tyson L., Kris MG, et al: The management of chemotherapy induced nausea and vomiting. Med Clin N Amer71:289-301,1987
6.
Jacobsen PB, Andrykowski MA, Redd WH, et al: Nonpharmacologic factors in the development of posttreatment nausea with adjuvant chemotherapy for breast cancer. Cancer61:379-385, 1988
7.
Lindley CM, Bernard S., Fields SM: Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol7:1142-1149,1989
8.
Kris MG, Gralla RJ, Clark RA, et al: Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol3:1379-1384,1985
9.
Jordan NS, Schauer PK, Schauer A., et al: The effect of administration rate on cisplatin-induced emesis . J Clin Oncol3:559-561, 1985
10.
Fetting JH, Grochow LB, Folstein MF, et al: The course of nausea and vomiting after high-dose cyclophosphamide . Cancer Treat Rep66:1487-1493,1982
Akwari OE: The gastrointestinal tract in chemotherapy-induced emesis: A final common pathway. Drugs25:18-34,1983 (suppl 1)
13.
Wampler G.: The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis. Drugs25:35-51, 1983 (suppl 1)
14.
Ison PJ, Peroutka SJ: Neurotransmitter receptor binding studies predict antiemetic efficacy and side effects. Cancer Treat Rep70:637-641, 1986
15.
Gunning SJ, Humphrey Ppa: Evidence for 5-HT3 receptor mediated release of an inhibitory transmitter in guinea pig isolated ileum. Br J Pharmacol91:359P, 1987 (abstr)
16.
Williams M. , Martin GE, Remy DC, et al: L-646, 462, a cyproheptadine-related antagonist of dopamine and serotonin with selectivity for peripheral systems . J Pharmacol Exp Ther229:775-781,1984
17.
Costall B., Domeney AM, Gunning SJ, et al: GR 38023F: A potent and novel inhibitor of cisplatin-induced emesis in the ferret. Br J Pharmacol90:90P, 1987 (abstr)
18.
Boyle EA, Miner WD, Sanger GJ: Different anticancer therapies evoke emesis by mechanisms that can be blocked by the 5-HT3 receptor antagonist BRL-43694. Br J Pharmacol91:418P, 1987 (abstr)
19.
Miner WD, Sanger GJ: Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol88:497-499, 1986
20.
Cubeddu LX, Hoffman IS, Fuenmayor NT, et al: Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med322:810-816,1990
21.
Grunberg SM , Stevenson LL, Russell CA, et al: Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol7:1137-1141, 1989
22.
Kris MG, Gralla RJ, Clark RA, et al: Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst81:42-46, 1989
23.
Einhorn LH, Nagy C., Werner K., et al: Ondansetron: A new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol8:731-735, 1990
24.
Longo D., Howser D., Wesley M., et al: Randomized double-blind crossover trial of scopolamine vs. placebo administered by transcutaneous patch for the control of chemotherapy induced emesis. Proc Am Assoc Cancer Res & Am Soc Clin Oncol22:161, 1981 (abstr)
25.
Meyer RB, O'Mara V., Reidenberg MM: A controlled clinical trial of the addition of transdermal scopolamine to a standard metoclopramide and dexamethasone antiemetic regimen. J Clin Oncol5:1994-1997,1987
26.
Lissoni P., Barni S., Crispino S., et al: Synthetic enkephalin analog in the treatment of cancer chemotherapy-induced vomiting. Cancer Treat Rep71:665-666, 1987 (letter)
27.
Dullemond-Westland AC, Neijt JP, Nortier Jwr, et al: Buprenorphine versus domperidone in chemotherapy-induced emesis: A pilot study. Radiother Oncol6:127-133, 1986
28.
McCarthy LE , Borison HL: Antiemetic activity of nabilone, a cannabinol derivative, reversed by naloxone in awake cats. Pharmacologist19:230, 1977 (abstr)
29.
Gralla RJ, Itri LM, Pisko SE, et al: Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med305:905-909, 1981
30.
Carr BI, Bertrand M., Browning S., et al: A comparison of the antiemetic efficacy of prochlorperazine and metoclopramide for the treatment of cisplatin-induced emesis: A prospective, randomized, double-blind study. J Clin Oncol3:1127-1132, 1985
31.
Strum SB, McDermed JE, Liponi DF: High-dose intravenous metoclopramide vs. combination high-dose metoclopramide + dexamethasone in preventing cisplatin-induced nausea and emesis: A single blind crossover comparison of antiemetic efficacy. J Clin Oncol3:245-251,1985
32.
Bruera ED, Roca E., Cedaro L., et al: Improved control of chemotherapy induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide . Cancer Treat Rep67:381-383,1983
33.
Agostinucci WA, Gannon RH, Golub GR, et al: Continuous iv infusion versus multiple bolus doses of metoclopramide for prevention of cisplatin-induced emesis. Clin Pharm7:454-457,1988
34.
Kris MG, Gralla RJ, Tyson LB, et al: Controlling delayed vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol7:108-114,1989
35.
Strum SB, McDermed JE, Streng B., et al: Combination metoclopramide and dexamethasone-An effective antiemetic regimen in outpatients receiving doxorubicin/ cyclophosphamide chemotherapy . Proc Am Soc Clin Oncol3:105,1984 (abstr)
36.
Edge SB, Funkhouser WK, Berman A., et al: High-dose oral and intravenous metoclopramide in doxorubicin/ cyclophosphamide induced emesis. Am J Clin Oncol10:257-263, 1987
37.
Kris MG, Gralla RJ, Clark RA, et al: Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy . J Clin Oncol6:659-662, 1988 38. Tyson LB, Clark RA, Gralla RJ: High-dose metoclopramide: Control of dacarbazine-induced emesis in a preliminary trial. Cancer Treat Rep66:2108, 1982 (letter)
38.
Basurto C., Roila F., Tonato E., et al: Antiemetic activity of high-dose metoclopramide combined with methylprednisolone vs. metoclopramide alone in dacarbazine-treated cancer patients. Proc Am Soc Clin Oncol7:290, 1988 (abstr)
39.
Craig JB, Powell BL, White DR, et al: Antiemetic therapy in patients treated with high-dose cytosine arabinoside. Oncology44:90-92, 1987
40.
Kris MG, Gralla RJ, Clark RA, et al: Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: Improved subjective effectiveness over the combination of diphenhydramine + metoclopramide plus dexamethasone. Cancer Treat Rep69:1257-1262, 1985
41.
Kris MG, Gralla RJ, Clark RA, et al: Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. Cancer60:2816-2822, 1987
42.
Kinzie B.: Treatment of stomatitis associated with antineoplastic-drug therapy . Clin Pharm7:14-17, 1988
43.
DeVita V, Hellman S, Rosenberg S (eds): Cancer, Principles and Practice of Oncology (ed 3). Philadelphia, PA, Lippincott , 1989
44.
National Institutes of Health Consensus Development Conference Statement: Oral Complications of Cancer Therapies: Diagnosis, Prevention and Treatment. US Department of Health and Human Services, April 17-19, 1989 46. Pfeiffer P., Hansen S., Madsen E., et al: Sucralfate prophylaxis of chemotherapy induced stomatitis. Proc Am Soc Clin Oncol8:665, 1989 (abstr)
45.
Shenep J., Kalwinsky D., Hutson P., et al: Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. J Pediatr113:758-763, 1988
46.
Clark P., Slevin M.: Allopurinol mouthwash and 5-Fluorouracil induced oral toxicity. Eur J Surg Oncol11:267-268,1985
47.
Loprinzi C. , Cianflone S., Dose A., et al: A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-Fluorouracil-induced stomatitis. Cancer65:1879-1882,1990
48.
McGaw W., Belch A.: Oral complications of acute leukemia: Prophylactic impact of a chlorhexidine mouth rinse regimen. Oral Surg Oral Med Oral Pathol60:275-280, 1985
49.
Ferretti G. , Ash R., Brown A., et al: Chlorhexidine for prophylaxis against oral infections and associated complications in patients receiving bone marrow transplants. J Am Dent Assoc114:461-467, 1987
50.
Bubley G., Chapman B., Chapman S., et al: Effect of acyclovir on radiation and chemotherapy induced mouth lesions. Antimicrob Agents Chemother33:862-865, 1989
51.
Mahood D., Dose A., Loprinzi C., et al: Inhibition of 5-fluorouracil induced stomatitis by oral cryotherapy . J Clin Oncol (in press)
52.
Chabner BA: Pyrimidine antagonists, in Chabner BA (ed): Pharmacologic Principles of Cancer Treatment. Philadelphia, PA, Saunders, 1982 , p 191
53.
Knobf M., Fischer D., Welsh-McCaffrey D.: Cancer Chemotherapy. Treatment and Care (ed 2). Boston, MA, Hall, 1984
54.
Ries F., Klastersky J.: Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis8:368-379, 1986
55.
Healey HG, Clarkson AR: Renal complications of cytotoxic therapy. Aust N Z J Med13:531-539,1983
56.
Madias NE, Harrington JT: Platinum nephrotoxicity. Am J Med65:307-314, 1978
57.
Blachley JD , Hill- JB: Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med95:628-632, 1981
58.
Hutchison FN , Perez EA, Gandara DR, et al: Renal salt wasting in patients treated with cisplatin. Ann Intern Med108:21-25, 1988
59.
Schilsky RL , Anderson T.: Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med90:929-931, 1979
60.
Schilsky RL , Barlock A., Ozols RF: Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep66:1767-1769, 1982
61.
Sulkes A., Collins JM: Reappraisal of some dosage adjustment guidelines. Cancer Treat Rep71:229-233, 1987
62.
Kwong PW, Kennedy BK: Adriamycin and cisplatinum in advanced genitourinary neoplasms with poor renal function. Proc Am Assoc Cancer Res & Am Soc Clin Oncol18:317, 1977 (abstr)
63.
Reece PA, Stafford I., Russell J., et al: Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol5:304-309, 1987
64.
Earhart RH, Martin PA, Tutsch KD, et al: Improvement in the therapeutic index of cisplatin by pharmacologically induced chloruresis in the rat. Cancer Res43:1187-1194,1983
65.
Litterst CL : Alterations in the toxicity of cisdichlorodiammine-platinum-II and in tissue localization of platinum as a function of Nacl concentration in the vehicle of administration. Toxicol Appl Pharmacol61:99-108, 1981
66.
Ozols RF, Corden BJ, Jacob J., et al: High-dose cisplatin in hypertonic saline. Ann Intern Med100:19-24,1984
67.
Pfeifle CE, Howell SB, Felthouse RD, et al: High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol3:237-244,1985
68.
Glover D., Glick JH, Weiler C., et al: WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma. J Clin Oncol5:574-578, 1987
69.
Qazi R., Chang Ayc, Borch RF, et al: Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a chemoprotector from toxic effects of cisplatin. J Natl Cancer Inst80:1486-1488,1988
70.
Macaulay VM, Begent Rhj, Phillips ME, et al: Prophylaxis against hypomagnesemia induced by cisplatinum combination chemotherapy. Cancer Chemother Pharmacol9:179-181, 1982
71.
Ashraf M., Riggs JE, Wearden S., et al: Prospective study of nerve conduction parameters and serum magnesium following cisplatin therapy. Gynecol Oncol37:29-33, 1990
72.
Liegler DG, Henderson ES, Hahn MA, et al: The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther10:849-857, 1970
73.
Stockley IH : Methotrexate-NSAID interactions. Drug Intell Clin Pharm21:546, 1987 (letter)
74.
Ellison NM, Servi RJ: Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: A possible adverse effect due to concomitant indomethacin administration . Cancer Treat Rep69:342-343, 1985 .
75.
Thyss A., Milano G., Kubar J., et al: Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet1:256-258, 1986
76.
Milano G., Perrin A., Thyss A., et al: The interaction between methotrexate and ketoprofen: Pharmacokinetic and biological analysis in rabbit. Proc Am Assoc Cancer Res30:536, 1989 (abstr)
77.
Nirenberg A. , Mosende C., Mehta BM, et al: High-dose methotrexate with citrovorum factor rescue: Predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat Rep61:779-783, 1977
78.
Weiss RB: Streptozocin: A review of its pharmacology, efficacy, and toxicity . Cancer Treat Rep66:427-438, 1982
79.
Giroux L., Bettez P., Giroux L.: Mitomycin-C nephrotoxicity: A clinicopathologic study of 17 cases . Am J Kidney Dis6:28-39, 1985
80.
Doll DC, Weiss RB, Issell BF: Mitomycin: Ten years after approval for marketing. J Clin Oncol3:276-286, 1985
81.
Lesesne JB, Rothschild N., Erickson B., et al: Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a National Registry. J Clin Oncol7:781-789,1989
82.
Cantrell JE , Phillips TM, Schein PS: Carcinoma-associated hemolytic-uremic syndrome. A complication of mitomycin C chemotherapy. J Clin Oncol3:723-734,1985
83.
Korec S., Schein PS, Smith FP, et al: Treatment of cancer-associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion. J Clin Oncol4:210-215, 1986
84.
Balis FM, Holcenberg JS, Bleyer WA: Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet8:202-232, 1983
85.
Balis FM: Pharmacokinetic drug interactions of commonly used anticancer drugs . Clin Pharmacokinet11:223-235, 1986
86.
Bennett WM, Pastore L., Houghton DC: Fatal pulmonary bleomycin toxicity in cisplatin-induced renal failure . Cancer Treat Rep64:921-924, 1980
87.
Crooke ST, Comis RL, Einhorn LH, et al: Effects of variations in renal failure on the clinical pharmacology of bleomycin administered as an IV bolus. Cancer Treat Rep61:1631-1636,1977
88.
Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol7:1748-1756, 1989
89.
Egorin MJ, Van Echo DA, Olman EA, et al: Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diammincyclobutanedicarboxylatoplatinum . Cancer Res45:6502-6506, 1985
90.
Kroener J., Green M.: Cyclophosphamide dose in renal failure. Am J Med64:725-726,1978 (letter)
91.
Humphrey RL , Kvols LK: The influence of renal insufficiency on cyclophosphamide induced hematopoietic depression and recovery. Proc Am Assoc Cancer Res & Am Soc Clin Oncol15:84, 1974 (abstr)
92.
Juma FD, Rogers HJ, Trounce JR: Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol19:443-451,1981
93.
Arbuck SG, Douglass HO, Crom WR, et al: Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol4:1690-1695, 1986
94.
D'Incalci M. , Rossi C., Zucchetti M., et al: Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res46:2566-2571, 1986
95.
Pratt CB, Green AA, Horowitz ME, et al: Central nervous system toxicity following the treatment of pediatric patients with ifosfamide and mesna. J Clin Oncol4:1253-1261,1986
96.
Gelman RS, Taylor SG: Cyclophosphamide, methotrexate and 5-fluoro-uracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using dosages based on creatinine clearance. J Clin Oncol2:1404-1413, 1984
97.
O'Dwyer PJ, Wagner B., Leyland-Jones B., et al: 2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Ann Intern Med108:733-743, 1988
98.
Zalupski M. , Baker LH: Ifosfamide. J Natl Cancer Instit80:556-566, 1988
99.
Brock N., Pohl J.: The development of mesna for regional detoxification. Cancer Treat Rev10:33-43, 1983 (suppl A)
100.
Brade WP, Herdrich K., Varini M.: Ifosfamide. Pharmacology, Safety and Therapeutic Potential. Cancer Treat Rev12:1-47,1985
101.
Shaw JC, Rose Jwp: Infusion of Ifosphamide plus Mesna. Lancet1:1353-1354, 1984
102.
James CA, Mant TG, Rogers HJ: Pharmacokinetics of intravenous and oral sodium 2-mercaptoethanesulfonate (mesna) in normal subjects. Br J Clin Pharmacol23:561-568,1987
103.
Burkert H. , Lucker PW, Wetzelsberger N., et al: Bioavailability of orally administered mesna. Drug Res34:1597-1600, 1984
104.
Klein HO, Wickramanayake PD, Coerper C., et al: High-dose ifosfamide and mesna as continuous infusion over five days. Cancer Treat Rev10:167-173,1983 (suppl A)
105.
Loehrer PJ , Williams SD, Langefeld C., et al: Comparison of N-acetylcysteine and mesna as uroprotective agents in ifosfamide combination chemotherapy. Proc Am Soc Clin Oncol8:130,1989 (abstr)
Plotz PH, Klippel JH, Decker JL, et al: Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med91:221-223,1979
108.
Herzig RH, Hines JD, Herzig GH, et al: Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol5:927-932,1987
109.
Hande KR, Stein RS, McDonough DA, et al: Effects of high-dose cytarabine. Clin Pharmacol Ther31:669-674,1982
110.
Borgeat A. , de Muralt B., Stalder M.: Peripheral neuropathy associated with high-dose Ara-C therapy. Cancer58:852-854, 1986
111.
Capizzi RL , Poole M., Cooper MR, et al: Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase . Blood63:694-700,1984
112.
Gottlieb D. , Bradstock K., Koutts J., et al: The neurotoxicity of high-dose cytosine arabinoside is age-related. Cancer60:1439-1441, 1987
113.
Nand S., Messmore HL, Patel R., et al: Neurotoxicity associated with systemic high-dose cytosine arabinoside . J Clin Oncol4:571-575,1986
114.
Benger A., Browman GP, Walker IR, et al: Clinical evidence of a cumulative effect of high-dose cytarabine on the cerebellum in patients with acute leukemia: A Leukemia Intergroup Report . Cancer Treat Rep69:240-241, 1985
115.
Lopez JA, Agarwal RP: Acute cerebellar toxicity after high-dose cytarabine associated with CNS accumulation of its metabolite, uracil arabinoside. Cancer Treat Rep68:1309-1310, 1984
116.
Damon LE, Mass R., Linker CA: The association between cytarabine neurotoxicity and renal insufficiency . J Clin Oncol7:1563-1568,1989
117.
Cersosimo RJ: Cisplatin neurotoxicity. Cancer Treat Rev16:195-211,1989
118.
Schaefer SD , Wright CG, Post JD, et al: Cisplatinum vestibular toxicity. Cancer47:857-859, 1981
119.
Ozols RF, Ostchega Y., Myers CE, et al: High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol3:1246-1250, 1985
120.
Mollman JE : Cisplatin neurotoxicity. N Engl J Med322:126-127,1990 (editorial)
121.
Lindeman G. , Kefford R., Stuart-Harris R.: Cisplatin neurotoxicity . N Engl J Med323:64-65, 1990
122.
van der Hoop RG, Vecht CJ, van der Burg Mel, et al: Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med322:89-94, 1990
123.
Mollman JE , Glover DJ, Hogan WM, et al: Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-272 1. Cancer61:2192-2195, 1988
124.
Reddel RR, Kefford RF, Grant JM, et al: Ototoxicity in patients receiving cisplatin: Importance of dose and method of drug administration. Cancer Treat Rep66:19-23, 1982
125.
McHaney VA , Thibadeau G., Hayes FA, et al: Auditory function of children receiving cis-platinum chemotherapy. Proc Am Assoc Cancer Res & Am Soc Clin Oncol22:401, 1981 (abstr)
126.
Legha S., Dimery IW: High-dose cisplatin administration without hypertonic saline: Observation of disabling neurotoxicity. J Clin Oncol3:1373-1378, 1985
Rosenthal S., Kaufman S.: Vincristine neurotoxicity. Ann Intern Med80:733-737,1974
129.
Byrd RL, Rohrbaugh TM, Raney RB, et al: Transient cortical blindness secondary to vincristine therapy in childhood malignancies. Cancer47:37-40, 1981
130.
Jackson DV , Wells HB, Atkins JN, et al: Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med84:1016-1022, 1988
131.
Grigg AP, Shepherd JD, Phillips GL: Busulphan and phenytoin. Ann Intern Med111:1049-1050, 1989 (letter)
132.
Spivack SD : Procarbazine. Ann Intern Med81:795-800,1974
133.
Goren MP, Wright RK, Pratt CB, et al: Potentiation of ifosfamide neurotoxicity, hematotoxicity and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Cancer Res47:1457-1460, 1987
134.
Pratt CB, Green AA, Horowitz ME, et al: Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol4:1253-1261, 1986
135.
Chun HG, Leyland-Jones BR, Caryk SM, et al: Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep70:1225-1228, 1986
136.
Merkel DE, Griffin NL, Kagan-Hallet K., et al: Central nervous system toxicity with fludarabine. Cancer Treat Rep70:1449-1450,1986
137.
Spriggs DR , Stopa E., Mayer RJ, et al: Fludarabine phosphate infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res46:5953-5958, 1986
138.
Warrell RP , Berman E.: Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity . J Clin Oncol4:74-79, 1986
139.
Hohn DC, Raynor AA, Economou, JJ, et al: Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion. Cancer57:465-470, 1986
140.
Haq MM, Valdes LG, Peterson DF, et al: Fibrosis of extrahepatic biliary system after continuous hepatic artery infusion of floxuridine through an implantable pump. Cancer57:1281-1283, 1986
141.
Hohn D., Melnick J., Stagg R., et al: Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol3:98-102, 1985
142.
Northover Jma, Terblanche J.: A new look at the arterial supply of the bile duct and its surgical implications. Br J Surg66:379, 1979
143.
Gluck WL, et al: A reversible enteropathy complicating continuous hepatic artery infusion chemotherapy with 5-fluoro-2-deoxyuridine. Cancer56:2424-2427, 1985
144.
Menard DB, Gisselbrecht C., Marty M., et al: Antineoplastic agents and the liver. Gastroenterology78:142-164, 1980
145.
Woolley PV : Hepatic and pancreatic damage produced by cytotoxic drugs. Cancer Treat Rev10:117-137, 1983
146.
Dahl Mgc, Gregory MM, Scheuer PJ: Methotrexate hepatotoxicity in psoriasis. Comparison of two different dose regimens. Br J Med1:654-656, 1972
147.
Shulman HM, McDonald GB, Matthews D., et al: An analysis of hepatic veno-occlusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology79:1178-1191, 1980
148.
McDonald GB, Sharma P., Matthews DE, et al: The clinical course of 53 patients with veno-occlusive disease of the liver after marrow transplantation. Transplantation39:603-608,1985
149.
Antman K., Eder JP, Elias A., et al: High dose combination alkylating agent preparative regimen with autologous bone marrow support: The Dana Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep71:119-125, 1987
150.
Seipp CA: Adverse effects of treatment: Hair loss, in DeVita V, Hellman S, Rosenberg S (eds): Cancer, Principles and Practice of Oncology (ed 3). Philadelphia, PA, Lippincott, 1989 , pp 2135-2136
151.
Yasko J (ed): Nursing Management of Symptoms Associated With Chemotherapy (revised edition). Columbus, OH, Adria Laboratories, 1986
152.
Dean JC, Salmon SE, Griffith KS: Prevention of doxorubicin-induced hair loss with scalp hypothermia . N Engl J Med301:1427-1429,1979
153.
Symonds RP , McCormick CV, Maxted KJ: Adriamycin alopecia prevented by cold air scalp cooling. Am J Clin Oncol9:454-457, 1986
154.
Dorr R.: Antidotes to vesicant chemotherapy extravasations. Blood Rev4:41-60, 1990
155.
Etcubanas E., Wilbur J.: Uncommon side effects of adriamycin . Cancer Chemother Rep Part158:757-758, 1974 158. Souhami L., Feld R.: Urticaria following intravenous doxorubicin administration. J Am Med Assoc240:1624-1626, 1978
156.
Vogelzang N.: 'Adriamycin Flare': A skin reaction resembling extravasation. Cancer Treat Rep63:2067-2069, 1979
157.
Barlock A. , Howser D., Hubbard S.: Nursing management of Adriamycin extravasation . Am J Nurs137:94-96, 1979
158.
Petro J., Graham W., Miller S., et al: Experimental and clinical studies of ulcers induced with adriamycin . Surg Forum30:535-537,1979
159.
Cohen M.: Amelioration of adriamycin skin necrosis: An experimental study. Cancer Treat Rep63:1003-1004,1979 163. Barr R., Sertic J.: Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents: A study of active intervention. Br J Cancer44:267-269, 1981
160.
Coleman J. , Walker A., Didolkar M.: Treatment of adriamycin-induced skin ulcers: A prospective controlled study. J Surg Oncol22:129-135, 1983
161.
Loth T., Eversmann W.: Treatment methods for extravasations of chemotherapeutic agents: A comparative study. J Hand Surg11A:388-396, 1986
162.
Dorr R., Alberts D., Chen H.: The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse. Cancer Chemother Pharmacol5:17-20,1980
163.
Wolgemuth R., Myers C., Luce J., et al: Doxorubicin extravasation ulceration: Animal model development and testing of potential antidotes. Proc Am Assoc Cancer Res23:171, 1982 (abstr)
164.
Olver I., Aisner J., Hament A., et al: A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol6:1732-1735, 1988
165.
Gaze N.: Tissue necrosis caused by commonly used intravenous infusions. Lancet1:417-419,1978
166.
Jackson I. , Robinson D.: Severe tissue damage following accidental subcutaneous infusion of bicarbonate solution. Scott Med J21:200-201, 1976
167.
Herrera D. , Burnham N.: DMSO and extravasation of mitomycin . Oncol Nurs Forum16:155,1989
168.
Moossa A, Robson M, Schimpff S (eds): Comprehensive Textbook of Oncology. Baltimore, MD, Williams & Wilkins, 1986
169.
Von Hoff D. , Rozencweig M., Layard M., et al: Daunomycin-induced cardiotoxicity in children and adults: A review of 110 cases. Am J Med62:200-208, 1977
170.
Torti FM, Lum BL: Adverse effects of treatment: Cardiac toxicity, in DeVita V, Hellman S, Rosenberg S (eds): Cancer, Principles and Practice of Oncology (ed 3). Philadelphia, PA, Lippincott, 1989 , pp 2153-2161
171.
Schwartz RG , McKenzie WB, Alexander J., et al: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy . Am J Med82:1109-1118, 1987
172.
Green M., Speyer J., Stacy P., et al: ICRF-187 prevents doxorubicin cardiotoxicity: Results of a randomized clinical trial. Proc Am Soc Clin Oncol6:28, 1987 (abstr)
173.
Underwood DA, Groppe CW, Tsai AR, et al: Coronary insufficiency and 5-fluorouracil therapy. Cleveland Clin Q50:29-31, 1983
174.
Dent R., McColl I.: 5-Fluorouracil and angina. Lancet1:347-348, 1975
175.
Burger A., Mannino S.: 5-Fluorouracil-induced coronary vasospasm. Am Heart J114:433-436, 1987
176.
Sanani S., Spaulding M., Masud A., et al: 5-FU cardiotoxicity. Cancer Treat Rep65:1123-1125, 1981
177.
Weiss R., Grillo-Lopez A., Marsoni S., et al: AMSA associated cardiotoxicity: An analysis of 82 cases. J Clin Oncol4:918-928,1986
178.
Praga C., Beretta G., Vigo P., et al: Adriamycin cardiotoxicity: A survey of 1273 patients. Cancer Treat Rep63:827-834, 1979
179.
Cazin B., Gorin N., Laporte J., et al: Cardiac complications after bone marrow transplantation: A report on a series of 63 consecutive transplantations. Cancer57:2061-2069,1986
180.
Hartmann L. , Frytak S., Richardson R., et al: Life-threatening bleomycin pulmonary toxicity with ultimate reversibility. Chest98:497-499, 1990
181.
Stover DE: Adverse effects of treatment: Pulmonary toxicity, in DeVita V, Hellman S, Rosenberg S (eds): Cancer, Principles and Practice of Oncology (ed 3). Philadelphia, PA, Lippincott, 1989 , pp 2164-2169
182.
O'Driscoll B., Hasleton P., Taylor P., et al: Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in Childhood . N Engl J Med323:378-382,1990
183.
Gaetani P. , Silvani V., Butti G., et al: Nitrosourea derivatives-induced pulmonary toxicity in patients treated for malignant brain tumors. Early subclinical detection and its prevention. Eur J Cancer Clin Oncol23:267-271, 1987
